Top Markets
Coin of the day
National Graphite Corp. National Graphite Corp.

National Graphite Corp.

NGRC
株式のランク #35948
National Graphite Corp. (NGRC), operating through its subsidiary Biotech... National Graphite Corp. (NGRC), operating through its subsidiary Biotech Development Corp., functions as a biopharmaceutical enterprise specializing in risk and cost-sharing models. The company establishes partnerships with clinical-stage firms dedicated to developing novel biological entities or innovative therapeutic platforms. These collaborations aim to address a wide spectrum of health conditions, encompassing common illnesses, rare disorders, and those with significant unmet medical requirements. Among its key pipeline developments is ELAFIN, a drug candidate identified as a human-identical protein. ELAFIN is being developed specifically for the management of postoperative inflammatory complications. The advancement of ELAFIN is further supported by a collaboration agreement with Proteo Inc. Founded in 2006, National Graphite Corp. was formerly known as Lucky Boy Silver Corporation until it officially adopted its current name in May 2012. The company maintains its operational headquarters in Duesseldorf, Germany.
株価
$0.021
最終同期: 2026-08-13
時価総額
$3.24M
変化(1日)
0.00%
変化(1年)
-46.15%
US
取引 National Graphite Corp. (NGRC)

カテゴリー

National Graphite Corp.(NGRC)の利益
2026 時点の利益 TTM: 0
National Graphite Corp. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
National Graphite Corp. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。